Atlanta, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, announced today it has signed a contract with a partner for the use of RevID at a 350-bed medical center based in California. Through its automated charge reconciliation, RevID will contribute to improved revenue integrity and financial performance.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“Our partners are entrusted with helping their clients improve operational and financial results, and we appreciate their faith in RevID’s ability to optimize charge capture at this medical center,” said Ben Stilwill, President, Streamline Health. “We look forward to accelerating the adoption of our unique, innovative solutions through our partners to help our nation’s healthcare providers receive accurate payment for the services they offer.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
dThis email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.33 |
| Daily Volume: | 0 |
| Market Cap: | US$23.250M |
May 01, 2025 January 22, 2025 December 18, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
